# Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6

> **NCT03303599** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 2118 (actual)

## Conditions studied

- Hepatitis C

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03303599
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-13
- **Primary completion:** 2020-01-24
- **Final completion:** 2020-01-24
- **Target enrollment:** 2118 (ACTUAL)
- **Last updated:** 2021-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03303599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03303599, "Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03303599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*